|
Biomarkers of coagulation, fibrinolysis, endothelial injury, and inflammation in all patients upon entry into the PROWESS trial (n = 1690) |
||||
| Biomarkers |
n |
Normal range |
Median level (25th–75th percentile) |
Abnormal patients (%) |
|
|
||||
| Procoagulant activity |
||||
| D-dimer (μg/ml) |
1550 |
0–0.39 |
4.2 (2.2–8.3) |
99.7a |
| TAT (μg/l) |
397 |
1–4.1 |
11 (7.4–19.7) |
95.5a |
| F1.2 (nmol/l) |
396 |
0.44–1.1 |
1.8 (1.1–2.6) |
77.5a |
| Anticoagulant activity |
||||
| Protein C (%) |
1574 |
81–173 |
48 (31–65) |
87.6b |
| Protein S (%) |
1541 |
60–155 |
36 (22–57) |
77.8b |
| AT (%) |
1558 |
80–120 |
59 (44–75) |
81.7b |
| Global coagulation tests |
||||
| Platelet counts (109/l) |
1419 |
140–400 |
182 (118–251) |
32.7b |
| PT (seconds) |
1558 |
10.6–14.5 |
18.7 (16.5–22.0) |
93.4a |
| APTT (seconds) |
1561 |
21–39 |
42.6 (36.3–50.4) |
63.1a |
| Fibrinolytic activity |
||||
| PAI-1 (AU/ml) |
298 |
4–37.8 |
34 (20–64) |
44.0a |
| TAFI (μg/ml) |
319 |
2.8–9.2 |
4.6 (3.1–6.5) |
17.6b |
| α2-AP (%) |
319 |
80–120 |
98 (81–115) |
51.1b |
| Plasminogen (%) |
316 |
64–111 |
61 (48–75) |
57.3b |
| Endothelial injury |
||||
| sTM (ng/ml) |
314 |
18–53 |
73 (51–117) |
72.0a |
| Inflammatory marker |
||||
| IL-6 (pg/ml) |
1635 |
0.38–10.1 |
492 (144–2574) |
98.5a |
|
aPercentage of patients with values higher than the upper limit of normal. bPercentage of patients with values lower than the lower limit of normal. α2-AP, α2-antiplasmin; APTT, activated partial thromboplastin time; AT, antithrombin; F1.2, prothrombin fragment 1.2; IL, interleukin; PAI, plasminogen activator inhibitor; PT, prothrombin time; TAFI, thrombin-activatable fibrinolysis inhibitor; sTM, soluble thrombomodulin; TAT, thrombin–antithrombin complex. | ||||
Kinasewitz et al. Critical Care 2004 8:R82 |
||||